1. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2022; 102(5S): S1-S127. doi: 10.1016/j.kint.2022.06.008. 2. Expert Group on Kidney Clinical Quality Control Center in Shanghai. Guidelines for early screening, diagnosis, and prevention of chronic kidney disease (2022 edition). Chin J Nephrol 2022; 38(5): 453-64. doi: 10.3760/cma.j.cn441217-20210819-00067. 3. van de Wouw J, Broekhuizen M, Sorop O, et al. Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets.Front Physiol 2019; 10: 1108. doi: 10.3389/fphys.2019.01108. 4. Thomas MC, Cooper ME, Zimmet P.Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 2016; 12(2): 73-81. doi: 10.1038/nrneph.2015.173. 5. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599-726. doi: 10.1093/eurheartj/ehab368. 6. Wang H, Chai K, Du M, et al.Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis. Circ Heart Fail 2021;14(10): e008406. doi: 10.1161/CIRCHEARTFAILURE.121.008406. 7. Clase CM, Carrero JJ, Ellison DH, et al.Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2020; 97(1): 42-61. doi: 10.1016/j.kint.2019.09.018. 8 8.Simon LV, Hashmi MF, Farrell MW. Hyperkalemia. [Updated 2022 Oct 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 January. 9. Bian J, Zuo L, Zhao H, et al.Epidemiology and treatment pattern of hyperkalemia among outpatients in China: a descriptive study using an administrative database in China. Chin J Blood Purif 2020; 19(11): 726-9. doi: 10.3969/j.issn.1671-4091.2020.11.002. (Chinese) 10. Kanda E, Rastogi A, Murohara T, et al.Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol 2023; 24(1): 18. doi: 10.1186/s12882-022-03054-5. 11. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2020; 98(4S): S1-S115. doi: 10.1016/j.kint.2020.06.019. 12. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021; 99(3S): S1-S87. doi: 10.1016/j.kint.2020.11.003. 13. Heidenreich PA, Bozkurt B, Aguilar D, et al.2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. 14. Chinese Society of Nephrology. Guidelines for early screening, diagnosis, prevention and treatment of chronic kidney disease (2022 Edition). Chin J Nephrol 2022; 38(5): 453-64. doi: 10.3760/cma.j.cn441217-20210819-00067. 15. Chinese Society of Nephrology. Guidelines for hypertension management in patients with chronic kidney disease in China (2023). Chin J Nephrol 2023; 39(1): 48-80. doi: 10.3760/cma.j.cn441217-20220630-00650. 16. Heart Failure Group of Cardiovascular Physician Branch of Chinese Medical Doctor Association, Expert Consensus Working Group on Management of Hyperkalemia in Patients with Heart Failure in China. Expert consensus on management of hyperkalemia in patients with heart failure in China. Chin J Med 2021; 101(42):3451-8. doi: 10.3760/cma.j.cn112137-20210624-01430. 17. Chinese Medical Doctor Association Heart Failure Professional Committee, National Cardiovascular Expert Committee Heart Failure Professional Committee, Chinese Journal of Heart Failure and Cardiomyopathy Editorial Board. Expert consensus on ion management for patients with heart failure in China. Chin J HF CM 2020; 4(1): 16-31. doi: 10.3760/cma.j.cn101460-20200114-00004. 18. Expert Group of Nephrology Branch of Chinese Medical Association. Expert consensus on serum potassium management practice in patients with chronic kidney disease in China. Chin J Nephrol 2020; 36(10): 781-92. doi: 10.3760/cma.j.cn441217-20200721-00139. 19. Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. (KDIGO) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024, 105(Suppl 4S): S117-S314. 20. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145:e895-e1032. doi: 10.1161/CIR.0000000000001063 21. Zhang J, He X, Wu J.The impact of hyperkalemia on mortality and healthcare resource utilization among patients with chronic kidney disease: a matched cohort study in China. Front Public Health 2022;10: 855395. doi: 10.3389/fpubh.2022.855395. 22. Expert Group of Guidelines on the Management of Hyperkalemia in Maintenance Hemodialysis Patients in China. Guideline on the management of hyperkalemia in maintenance hemodialysis patients in China. Chin J Blood Purif2022; 21(Suppl): S1-S16. (Chinese) 23. Xue C, Mei C.Long-term management of hyperkalemia in chronic kidney disease. Chin [J] Nephrol. 2021, 37(4): 380-4. DOI: 10.3760/cma.j.cn441217-20200623-00056. 24. Dalkey N, Helmer O.An experimental application of the Delphi method to the use of experts. Management Sci 1963; 9: 458-67. 25. Diamond IR, Grant RC, Feldman BM, et al.Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 2014; 67(4): 401-9. 26. Jing X, Xu L, Qin W, et al.The willingness for downward referral and its influencing factors: a cross-sectional study among older adults in Shandong, China. Int J Environ Res Public Health 2020; 17(1): 369. doi: 10.3390/ijerph17010369. 27. Xiao Y, Chen X, Li Q, et al.Towards Healthy China 2030: modeling health care accessibility with patient referral. Soc Sci Med 2021; 276: 113834. doi: 10.1016/j.socscimed.2021.113834. 28. Bernier-Jean A, Wong G, Saglimbene V, et al.Dietary potassium intake and all-cause mortality in adults treated with hemodialysis. Clin J Am Soc Nephrol 2021; 16: 1851-61. doi: 10.2215/CJN.08360621. 29. Yuan Lu, Bi-Cheng Liu & Hong Liu. An evaluation of sodium zirconium cyclosilicate: a new treatment option for hyperkalemia in China. Expert Opin Pharmacother 2023; doi:10.1080/14656566.2022.2161884 30. Brown R, Bratton SL, Cabana MD, et al.Physician asthma education program improves outcomes for children of low-income families. Chest. 2004;126(2): 369-74. doi: 10.1378/chest.126.2.369. 31. Silva-Cardoso J, Brito D, Frazão JM, et al.Management of RAASi-associated hyperkalemia in patients with cardiovascular disease. Heart Fail Rev 2021; 26(4): 891-6. doi: 10.1007/s10741-020-10069-3. 32. Burton JO, Coats AJS, Kovesdy CP, et al.An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum. Eur [J] Heart Fail. 2022; 24(9): 1467-77. doi: 10.1002/ejhf.2612. |